Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Nurtec ODT / Vydura (rimegepant by Year
Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — U.S. reported YoY (%) (%)
Pfizer Nurtec ODT / Vydura (rimegepant: 11.0% in FY2025, down 20.0 pts from a year earlier.
Latest, FY2025
11.0%
Period ended Dec 31, 2025
Change on a year earlier
-20.0 pts
31.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Nurtec ODT/Vydura | 1,424 | 1,263 | 13% | 13% | 1,322 | 1,193 | 11% | 102 | 69 | 46% | 44%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.0% | -20.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 31.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Pfizer Nurtec ODT / Vydura (rimegepant (%), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/nurtec-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.